News & events

Press releases

8 July 2020, Sophia Antipolis, France

Median Technologies:  Strong business activity for the first half of 2020 (unaudited figures)

First-half revenue up 47.9% to €5.9 million, compared with €4.0 million in H1 2019 – 7 consecutive quarters of revenue growth – Order backlog to €53.6 million as of June 30th, 2020, up 40% compared with order backlog as of December 31st, 2019 and up 74.6% compared with order backlog as of June 30th, 2019 – Cash and cash equivalents expected to reach €19.4 million

Read more
See all press releases


November 29 - December 4, 2020 | Virtual Event

RSNA 2020

Median will be exhibiting at the RSNA 2020 Annual Meeting, which will take place from November 29 to December 4. Stop by our virtual booth to learn more about our  Imaging Phenomics platform iBiopsy®. Happy to see you there during the whole exhibition duration, from November 30 to December 3.

Visit conference website
See all conferences

In the press

iBiopsy® for Precision Medicine

Check out our paper published in the European Medical Journal on December 13, 2018 in order to educate the oncology specialists across Europe and the US as to the high-throughput artificial intelligence powered image-base phenotyping platform, iBiopsy® ->


A high-throughput artificial intelligence-powered image-based phenotyping platform, iBiopsy® (Median Technologies, Valbonne, France), which aims to improve precision medicine, is discussed in the presented review. The article introduces novel concepts, including high-throughput, fully automated imaging biomarker extraction; unsupervised predictive learning; large-scale content-based image-based similarity search; the use of large-scale clinical data registries; and cloud-based big data analytics to the problems of disease subtyping and treatment planning. Unlike electronic health record-based approaches, which lack the detailed radiological, pathological, genomic, and molecular data necessary for accurate prediction, iBiopsy® generates unique signatures as fingerprints of disease and tumor subtypes from target images. These signatures are then merged with any additional omics data and matched against a large-scale reference registry of deeply phenotyped patients. Initial applications targeted include hepatocellular carcinoma and other chronic liver diseases, such as nonalcoholic steatohepatitis. This new disruptive technology is expected to lead to the identification of appropriate therapies targeting specific molecular pathways involved in the detected phenotypes to bring personalised treatment to patients, taking into account individual biological variability, which is the principal aim of precision medicine.

See all in the press


See all blog entries


APRIL 21, 2020 05:00PM CEST

The Evolution of Response Evaluation Criteria in Cancer Immunotherapy

The response evaluation of cancer immunotherapy requires differentiation from traditional chemotherapy; hence, it needs more precise criteria that are compatible with the observed response patterns and the well-documented mechanism of action of these novel treatments. This 30 minutes presentation + 15 minutes Q&A provides a review of the latest advances of imaging assessment for cancer immunotherapy evaluation in clinical trials.


o Lesson learnt – the evolution of response criteria in immunotherapy
o Overview of immune modified response criteria
o Challenging cases – pitfall of imaging interpretation


• Dr. Yan Liu, CMO, Median Technologies
• Dr. Antoine Iannessi, Medical Director iCRO, Median Technologies

Watch webinar video
See all webinars